Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis

Int J Clin Pharmacol Ther. 2009 Jan;47(1):61-4. doi: 10.5414/cpp47061.
No abstract available

MeSH terms

  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / metabolism
  • Benzenesulfonates / pharmacokinetics*
  • Benzenesulfonates / therapeutic use
  • Blood Specimen Collection
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Kidney Diseases / blood
  • Kidney Diseases / physiopathology
  • Kidney Diseases / therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / metabolism
  • Protein Kinase Inhibitors / pharmacokinetics*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / chemistry
  • Pyridines / metabolism
  • Pyridines / pharmacokinetics*
  • Pyridines / therapeutic use
  • Renal Dialysis*
  • Sorafenib
  • Time Factors

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • pyridine N-oxide
  • Sorafenib